Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

NCT07223814 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

875

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Bleximenib
DRUG: Cytarabine
DRUG: Daunorubicin or Idarubicin
DRUG: Placebo

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]